Diagnostic performance of US LI-RADS in hepatocellular carcinoma surveillance

被引:0
|
作者
Abduljabbar, Ahmed Haitham [1 ,2 ]
Wazzan, Mohammad A. [1 ,2 ]
机构
[1] King Abdulaziz Univ, Fac Med, Dept Radiol, Jeddah, Saudi Arabia
[2] King Abdulaziz Univ Hosp, Dept Radiol, Jeddah, Saudi Arabia
来源
EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE | 2023年 / 54卷 / 01期
关键词
Hepatocellular carcinoma; Surveillance; Liver cirrhosis; Ultrasound; Ultrasound LI-RADS; ALPHA-FETOPROTEIN MEASUREMENT; ULTRASOUND; DISEASE;
D O I
10.1186/s43055-023-01083-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
BackgroundLiver cirrhosis and chronic infection with hepatitis B virus are major risk factors for hepatocellular carcinoma (HCC). Guidelines recommend ultrasound (US) surveillance for population at risk of HCC. The US Liver Imaging Reporting and Data System (LI-RADS) aims at standardization of interpretation, reporting, and management recommendations for US surveillance examinations. The aim of this study is to assess the diagnostic accuracy of US LI-RADS in early HCC detection in patients at risk.ResultsThis retrospective study included patients with surveillance US between January 2018 and January 2020 who had a contrast-enhanced CT or MRI of the liver within 1 month from the date of US examination. Visualization scores and US categories were assigned according to the US LI-RADS lexicon. A total of 264 participants were eligible for the study. HCC was diagnosed in 33 participants. The US-3 category had a 39.4% sensitivity and 93.5% specificity for HCC detection. The US-2 category had a 45.4% sensitivity and 87% specificity for HCC detection. The visualization score C showed the highest number of HCC (19/33) and had the highest false-negative rate (76%, 13 of 17).ConclusionsBoth US-2 and US-3 categories showed high specificity and low sensitivity for HCC detection in the setting of surveillance of patients at high risk. Visualization score C had the highest risk for HCC and the highest rate of false-negative results. Intense surveillance by contrast-enhanced CT or MRI might be beneficial for patients with limited visualization scores B and C.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Hepatocellular Carcinoma in Evolution: Correlation with CEUS LI-RADS
    Nguyen, Stephanie A.
    Merrill, Christina D.
    Burrowes, David P.
    Medellin, G. Alexandra
    Wilson, Stephanie R.
    RADIOGRAPHICS, 2022, 42 (04) : 1028 - 1042
  • [22] Assessing Adherence to US LI-RADS Follow-up Recommendations in Vulnerable Patients Undergoing Hepatocellular Carcinoma Surveillance
    Choi, Hailey H.
    Kim, Stephanie
    Shum, Dorothy J.
    Huang, Chiung-Yu
    Shui, Amy
    Fox, Rena K.
    Khalili, Mandana
    RADIOLOGY-IMAGING CANCER, 2024, 6 (01):
  • [23] LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features
    Ayman Alhasan
    Milena Cerny
    Damien Olivié
    Jean-Sébastien Billiard
    Catherine Bergeron
    Kip Brown
    Paule Bodson-Clermont
    Hélène Castel
    Simon Turcotte
    Pierre Perreault
    An Tang
    Abdominal Radiology, 2019, 44 : 517 - 528
  • [24] Impact of Hepatocellular Carcinoma Etiology on the Performance of LI-RADS LR5
    Cheung, Chun Lam
    Tripathi, Vrijesh
    Chiang, Chi-Leung
    Chiu, Keith Wan Hang
    RADIOLOGY, 2024, 312 (02)
  • [25] Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS
    Hu, Yi-Xin
    Shen, Jing-Xian
    Han, Jing
    Mao, Si-Yue
    Mao, Ru-Shuang
    Li, Qing
    Li, Fei
    Guo, Zhi-Xing
    Zhou, Jian-Hua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features
    Alhasan, Ayman
    Cerny, Milena
    Olivie, Damien
    Billiard, Jean-Sebastien
    Bergeron, Catherine
    Brown, Kip
    Bodson-Clermont, Paule
    Castel, Helene
    Turcotte, Simon
    Perreault, Pierre
    Tang, An
    ABDOMINAL RADIOLOGY, 2019, 44 (02) : 517 - 528
  • [27] Clinicoradiographic predictors of progression of an intermediate hepatic lesion (LI-RADS 3) to hepatocellular carcinoma (LI-RADS 5)
    Hannan, Lindsay M.
    Ojeda, Patricia I.
    Mieloszyk, Rebecca J.
    Harris, William P.
    Park, James O.
    Bhargava, Puneet
    HEPATOMA RESEARCH, 2021, 7 : 7 - 78
  • [29] Diagnostic performance of intravascular perfusion based contrast-enhanced ultrasound LI-RADS in the evaluation of hepatocellular carcinoma
    Zuo, Dongsheng
    Yang, Kefeng
    Wu, Size
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2021, 78 (04) : 429 - 437
  • [30] Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI
    Ko, A.
    Park, H. J.
    Lee, E. S.
    Park, S. B.
    Kim, Y. K.
    Choi, S-Y
    Ahn, S.
    CLINICAL RADIOLOGY, 2020, 75 (04) : 319.e1 - 319.e9